SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

08 янв 2025 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Activates 14th Hospital for its Adult AKI Pivotal Trial

23 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications

11 дек 2024 06:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical to Hold Business Update Conference Call on December 11, 2024

04 дек 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

03 дек 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

26 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

22 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

15 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

13 ноя 2024 17:05:22 Источник Nasdaq GlobeNewswire

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

06 ноя 2024 09:00:00 Источник Nasdaq GlobeNewswire

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

01 ноя 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

31 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

25 окт 2024 11:32:00 Источник Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

25 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

23 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

09 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

08 окт 2024 08:30:00 Источник Nasdaq GlobeNewswire